| Literature DB >> 28196853 |
Adil Bashir1,2, Kathryn L Bohnert3, Dominic N Reeds4, Linda R Peterson4, Adam J Bittel3, Lisa de Las Fuentes4, Christina A Pacak5, Barry J Byrne5, W Todd Cade6,4.
Abstract
Barth syndrome (BTHS) is an X-linked condition characterized by altered cardiolipin metabolism and cardioskeletal myopathy. We sought to compare cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with BTHS and unaffected controls and examine their relationships with cardiac function and exercise capacity. Children/adolescents and young adults with BTHS (n = 20) and children/adolescent and young adult control participants (n = 23, total n = 43) underwent 31P magnetic resonance spectroscopy (31P-MRS) of the lower extremity (calf) and heart for estimation of skeletal muscle and cardiac bioenergetics. Peak exercise testing (VO2peak) and resting echocardiography were also performed on all participants. Cardiac PCr/ATP ratio was significantly lower in children/adolescents (BTHS: 1.5 ± 0.2 vs. CONTROL: 2.0 ± 0.3, P < 0.01) and adults (BTHS: 1.9 ± 0.2 vs. CONTROL: 2.3 ± 0.2, P < 0.01) with BTHS compared to Control groups. Adults (BTHS: 76.4 ± 31.6 vs. CONTROL: 35.0 ± 7.4 sec, P < 0.01) and children/adolescents (BTHS: 71.5 ± 21.3 vs. CONTROL: 31.4 ± 7.4 sec, P < 0.01) with BTHS had significantly longer calf PCr recovery (τPCr) postexercise compared to controls. Maximal calf ATP production through oxidative phosphorylation (Qmax-lin) was significantly lower in children/adolescents (BTHS: 0.5 ± 0.1 vs. CONTROL: 1.1 ± 0.3 mmol/L per sec, P < 0.01) and adults (BTHS: 0.5 ± 0.2 vs. CONTROL: 1.0 ± 0.2 mmol/L sec, P < 0.01) with BTHS compared to controls. Blunted cardiac and skeletal muscle bioenergetics were associated with lower VO2peak but not resting cardiac function. Cardiac and skeletal muscle bioenergetics are impaired and appear to contribute to exercise intolerance in BTHS.Entities:
Keywords: Barth syndrome; energetics; exercise; mitochondria; muscle
Mesh:
Year: 2017 PMID: 28196853 PMCID: PMC5309577 DOI: 10.14814/phy2.13130
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Participant demographics, peak exercise testing, and echocardiography
| Control ( | BTHS ( |
| Control ( | BTHS ( |
| |
|---|---|---|---|---|---|---|
| Age (years) | 12 ± 3 | 13 ± 3 | 0.36 | 23 ± 5 | 27 ± 4 | 0.10 |
| Height (cm) | 154.5 ± 17.7 | 143.8 ± 14.2 | 0.08 | 175.7 ± 4.7 | 178.4 ± 6.7 | 0.39 |
| Weight (kg) | 47.3 ± 18.6 | 34.9 ± 12.4 | 0.04 | 84.5 ± 14.4 | 68.0 ± 12.6 | 0.02 |
| FFM (kg) | 38.9 ± 15.3 | 24.3 ± 6.7 | 0.003 | 65.7 ± 8.4 | 42.2 ± 7.2 | <0.001 |
| FFM (%) | 83 ± 7 | 68 ± 13 | <0.001 | 79 ± 8 | 64 ± 11 | 0.01 |
| FM (kg) | 8.0 ± 5.7 | 12.8 ± 10.2 | 0.12 | 18.5 ± 9.3 | 25.3 ± 9.8 | 0.17 |
| FM (%) | 17 ± 7 | 32 ± 13 | <0.001 | 21 ± 8 | 36 ± 11 | 0.01 |
| Resting HR (bpm) | 83 ± 7 | 85 ± 11 | 0.58 | 75 ± 19 | 74 ± 16 | 0.43 |
| Resting SBP (mmHg) | 106 ± 12 | 101 ± 12 | 0.28 | 137 ± 6 | 104 ± 9 | <0.001 |
| Resting DBP (mmHg) | 65 ± 10 | 67 ± 9 | 0.58 | 84 ± 9 | 65 ± 10 | 0.17 |
| Exercise variables | ||||||
|
| 36.1 ± 7.7 | 13.7 ± 3.2 | <0.001 | 35.7 ± 5.9 | 12.3 ± 3.5 | <0.001 |
| Peak watts | 143 ± 70 | 39 ± 10 | <0.001 | 239 ± 51 | 61 ± 11 | <0.001 |
| Peak RER | 1.1 ± 0.1 | 1.3 ± 0.2 | 0.002 | 1.2 ± 0.1 | 1.5 ± 0.2 | <0.001 |
| Peak HR | 184 ± 11 | 158 ± 22 | <0.001 | 186 ± 15 | 159 ± 11 | 0.001 |
| Peak SBP (mmHg) | 144 ± 19 | 116 ± 16 | <0.001 | 202 ± 24 | 137 ± 16 | <0.001 |
| Peak DBP (mmHg) | 70 ± 11 | 74 ± 16 | 0.47 | 88 ± 11 | 84 ± 11 | 0.70 |
| Echocardiography | ||||||
| LVM (g) | 94.6 ± 30.1 | 74.6 ± 28.6 | 0.13 | 149.7 ± 37.8 | 127.2 ± 25.6 | 0.29 |
| Ejection fraction (%) | 67 ± 4 | 63 ± 5 | 0.02 | 64 ± 5 | 57 ± 15 | 0.18 |
| Fractional shortening (%) | 40 ± 6 | 34 ± 11 | 0.08 | 36 ± 6 | 30 ± 8 | 0.05 |
| Global strain (%) | −21 ± 3 | −20 ± 2 | 0.25 | −18 ± 2 | −15 ± 3 | 0.05 |
Values are means ± SD.
FFM, fat‐free mass; FM, fat mass; VO2peak, volume of oxygen consumption during peak; LVM, left ventricular mass.
Figure 1Reference images of the heart. Location of saturation band and approximate sensitive region of the RF coil is also shown (A) Spectrum from a healthy control (B) and a participant with Barth syndrome (C) detailing the peaks of PCr, ATP, PDE, and 2,3 DPG. PCr resonance amplitude is reduced in spectrum from Barth participant with similar ATP amplitudes. The red dashed lines provide a visual cue of changes in PCr and ATP peaks. β‐ATP resonance in the spectra is diminished due to the bandwidth limitations of the adiabatic RF pulse. DPG, 2,3‐diphosphoglycerate; PDE, phosphodiester.
Resting cardiac and skeletal muscle bioenergetics
| Children | Adults | |||||
|---|---|---|---|---|---|---|
| Skeletal Muscle | Control ( | BTHS ( |
| Control ( | BTHS ( |
|
| pH | 7.0 ± 0.0 | 7.1 ± 0.1 | 0.45 | 7.0 ± 0.0 | 7.0 ± 0.0 | 0.48 |
| [PCr] (mmol/L) | 31.3 ± 1.9 | 35.8 ± 1.8 | <0.01 | 33.3 ± 2.5 | 35.8 ± 2.5 | 0.11 |
| [Pi] (mmol/L) | 3.0 ± 0.7 | 2.3 ± 1.2 | 0.06 | 2.8 ± 0.7 | 2.0 ± 0.8 | 0.08 |
| [PCr]/[Pi] | 11.0 ± 3.5 | 18.7 ± 7.5 | <0.01 | 13.2 ± 5.2 | 22.1 ± 11.9 | 0.10 |
| [PDE] (mmol/L) | 1.7 ± 0.7 | 2.6 ± 0.9 | 0.01 | 2.4 ± 0.8 | 2.9 ± 0.7 | 0.35 |
| [ADP] | 19.2 ± 4.3 | 10.6 ± 3.4 | <0.01 | 14.8 ± 5.6 | 9.7 ± 4.1 | 0.09 |
| Cardiac | ||||||
| [PCr]/[ATP] | 2.0 ± 0.2 | 1.5 ± 0.2 | <0.01 | 2.3 ± 0.2 | 1.9 ± 0.2 | <0.01 |
Values are means ± SD.
PCr, phosphocreatine concentration; Pi, inorganic phosphate concentration; PDE, phosphodiesterase concentration; ADP, adenosine diphosphate concentration; ATP, adenosine triphosphate concentration.
Figure 2Typical postexercise PCr recovery data. PCr amplitude (normalized to resting condition) for all participants (A) Adults, (B) Children/Adolescents). Error bars represent standard error. Representative PCr recovery data from adults (C) and children/adolescents (D) showing example of signal exponential fit.
Skeletal muscle bioenergetics during/postexercise
| Children | Adults | |||||
|---|---|---|---|---|---|---|
| Control ( | BTHS ( |
| Control ( | BTHS ( |
| |
| pH end | 7.0 ± 0.1 | 7.0 ± 0.1 | 0.60 | 7.0 ± 0.1 | 7.0 ± 0.2 | 0.73 |
| [ADP] end ( | 51.7 ± 14.3 | 54.9 ± 24.3 | 0.70 | 49.5 ± 6.4 | 59.6 ± 23.8 | 0.30 |
| TPCr (sec) | 31.4 ± 7.3 | 71.5 ± 21.3 | <0.01 | 35.0 ± 7.4 | 76.4 ± 31.6 | <0.01 |
| Vi (mmol/L per sec) | 0.3 ± 0.1 | 0.2 ± 0.1 | <0.01 | 0.3 ± 0.1 | 0.2 ± 0.1 | <0.01 |
| Qmax‐lin (mmol/L per sec) | 1.1 ± 0.3 | 0.5 ± 0.1 | <0.01 | 1.0 ± 0.2 | 0.5 ± 0.2 | <0.01 |
| Qmax‐ADP (mmol/L per sec) | 0.5 ± 0.2 | 0.3 ± 0.1 | <0.01 | 0.5 ± 0.2 | 0.3 ± 0.1 | <0.01 |
| ATPox (mM/L per min) | 20.6 ± 5.7 | 12.7 ± 4.5 | <0.01 | 20.0 ± 6.0 | 12.0 ± 3.3 | 0.02 |
Values are means ± SD.
ADP, adenosine diphosphate concentration; TPCr, Tau phosphocreatine; Vi, initial rate of PCr recovery; Qmax‐lin, Q maximum linear equation; Qmax‐ADP, Q maximum ADP equation, ADP, adenosine diphosphate concentration, BTHS, Barth syndrome.